Prestige Consumer Healthcare Inc.
NYSE:PBHMedical - Distribution
+$0.23 today
- Market cap
- $2.40B
- Beta
- 0.35
- P/E (TTM)
- 11.6
- EPS (TTM)
- $4.01
Volume 0.62M
Average 0.67M
PBH Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Prestige Consumer Healthcare Inc.NYSE: PBH
Depreciation & Amortization · Q1 FY2027 · quarter ended Jun 2026
Depreciation & amortization growth accelerates
Q1 FY2027 depreciation & amortization of $8.75M rose 14.2% year over year, ahead of the +8.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 4.8% from the prior quarter. Over 3 fiscal years it compounded at -1.4% a year.
Context
- Depreciation & amortization amounted to 2.9% of revenue in FY2026, up 0.2 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +14.2% holds above the trailing-twelve-month pace of +8.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2026
- 31.27M USD
- Year-over-year change
- +3.6%
- 4-year CAGR
- -0.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 31.27M | +3.6% |
| FY2025 | 2025-03-31 | 30.17M | -1.6% |
| FY2024 | 2024-03-31 | 30.68M | -6.0% |
| FY2023 | 2023-03-31 | 32.63M | +1.7% |
| FY2022 | 2022-03-31 | 32.09M | — |
Depreciation & Amortization vs competitors
How PBH compares with its peers on the latest reported figures
- PBH's LTM Jun 2026 depreciation & amortization of $32.36M is the 7th largest of the 11 companies compared; the peer median is $44.23M.
- Its year-over-year change of +8.9% is the 8th highest of 11, against a peer median of +11.9%.
- Depreciation & amortization amounts to 2.9% of revenue for PBH, versus a peer median of 4.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $204.78M | -1.5% | -5.1% | 9.5% | |
| LTM Mar 2026 | $88.73M | +3.7% | +33.7% | 11.3% | |
CONConcentra Group Holdings Parent, Inc. | LTM Sep 2026 | $79.99M | +12.4% | +1.0% | 3.4% |
| LTM Sep 2026 | $64M | +11.3% | -10.1% | 4.2% | |
| LTM Sep 2026 | $50.27M | +111.9% | +16.3% | 3.7% | |
| LTM Mar 2026 | $38.19M | +1.0% | +212.7% | 6.4% | |
| LTM Jun 2026 | $32.36M | +8.9% | -1.4% | 2.9% | |
| LTM Jun 2026 | $15.93M | +21.7% | +22.2% | 3.5% | |
| LTM Jun 2026 | $12.06M | +48.7% | +29.4% | 0.5% | |
HTFLHeartflow, Inc. Common Stock | LTM Sep 2026 | $9.44M | +9.0% | — | 4.0% |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $358K | +78.1% | +46.7% | — |
| Peer median (excluding PBH) | $44.23M | +11.9% | +22.2% | 4.0% | |
Competitors are the stored peer set for PBH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Net Income | 205.38M | (82.31M) | 209.34M | 214.61M | 190.3M |
| Depreciation & Amortization | 32.09M | 32.63M | 30.68M | 30.17M | 31.27M |
| Deferred Income Tax | 9.98M | (60.77M) | 23.07M | 14.41M | 22.7M |
| Stock-Based Compensation | 9.04M | 12.41M | 14.01M | 11.16M | 10.84M |
| Change in Working Capital | (10.95M) | (53.86M) | (39.83M) | (41.94M) | (17.62M) |
| Accounts Receivables | (24.65M) | (24.93M) | (6.32M) | (16.33M) | (3.69M) |
| Inventory | 663K | (42.23M) | 24.44M | (9.31M) | (1.6M) |
| Accounts Payables | 9.15M | 7.26M | (24.97M) | (19.41M) | (151K) |
| Other Working Capital | 3.89M | 6.04M | (32.98M) | 3.11M | (12.19M) |
| Other Non-Cash Items | 14.38M | 381.61M | 11.66M | 23.11M | 20.14M |
| Operating Cash Flow | 259.92M | 229.72M | 248.93M | 251.52M | 257.63M |
| Capital Expenditures | (9.64M) | (7.78M) | (9.55M) | (8.22M) | (11.18M) |
| Acquisitions (Net) | (246.87M) | (3.8M) | (10.56M) | (9.23M) | (123.74M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | (1.93M) |
| Investing Cash Flow | (256.51M) | (11.58M) | (20.11M) | (17.45M) | (136.84M) |
| Debt Repayment | (5.58M) | (137.75M) | (227.83M) | (139.54M) | 504K |
| Common Stock Issued | 7.04M | 0 | 0 | 14.8M | 4.29M |
| Common Stock Repurchased | 0 | (50M) | (25M) | (51.51M) | (156.28M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (9.03M) | 1.91M | 11.81M | (5.83M) | (4.57M) |
| Financing Cash Flow | (7.57M) | (185.85M) | (241.02M) | (182.08M) | (156.06M) |
| Effect of Forex Changes | (959K) | (982K) | 180K | (573K) | 1.26M |
| Net Change in Cash | (5.12M) | 31.3M | (12.02M) | 51.42M | (34.02M) |
| Free Cash Flow | 250.28M | 221.93M | 239.38M | 243.29M | 246.45M |
Prestige Consumer Healthcare Inc.
NYSE:PBH
Intrinsic Alpha fair value
Locked
Current Price
$50.62
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.